fosamprenavir has been researched along with bosentan anhydrous in 1 studies
Studies (fosamprenavir) | Trials (fosamprenavir) | Recent Studies (post-2010) (fosamprenavir) | Studies (bosentan anhydrous) | Trials (bosentan anhydrous) | Recent Studies (post-2010) (bosentan anhydrous) |
---|---|---|---|---|---|
174 | 55 | 37 | 1,836 | 215 | 630 |
Protein | Taxonomy | fosamprenavir (IC50) | bosentan anhydrous (IC50) |
---|---|---|---|
Endothelin receptor type B | Rattus norvegicus (Norway rat) | 0.095 | |
Endothelin receptor type B | Homo sapiens (human) | 0.3044 | |
Endothelin-1 receptor | Homo sapiens (human) | 0.2317 | |
Endothelin-1 receptor | Rattus norvegicus (Norway rat) | 0.0047 | |
Endothelin-1 receptor | Sus scrofa (pig) | 0.0075 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for fosamprenavir and bosentan anhydrous
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |